MREO 8-K 2026-11-09
Mereo BioPharma Group plc (MREO) 8-K dated 2026-11-09 — accession 0001193125-26-452716.
Mereo BioPharma Group plc (MREO) is a biotechnology company listed on US.
MREO: Mereo BioPharma Reports Third Quarter 2026 Financial Results
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported MREO revenue for 2025-12-31 was $500.0K. Net income was -$41.9M. MREO currently screens at market cap $48.7M.
Not investment advice. The MREO SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to provide an update before the end of the year.
Why it matters
- expects to provide an update before the end of the year.